Effect of Anthrax Immune Globulin on Response to BioThrax (Anthrax Vaccine Adsorbed) in New Zealand White Rabbits
Author(s) -
Nina Malkevich,
Subhendu Basu,
Thomas L. Rudge,
Kristin H. Clement,
Ajoy C. Chakrabarti,
Ronald T. Aimes,
Gary S. Nabors,
Mario H. Skiadopoulos,
Б. И. Ионин
Publication year - 2013
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00460-13
Subject(s) - anthrax vaccines , immune system , vaccination , immunology , antibody , virology , antigen , antibody response , anthrax toxin , microbiology and biotechnology , medicine , biology , immunization , dna vaccination , biochemistry , fusion protein , gene , recombinant dna
Development of anthrax countermeasures that may be used concomitantly in a postexposure setting requires an understanding of the interaction between these products. Anthrax immune globulin intravenous (AIGIV) is a candidate immunotherapeutic that contains neutralizing antibodies against protective antigen (PA), a component of anthrax toxins. We evaluated the interaction between AIGIV and BioThrax (anthrax vaccine adsorbed) in rabbits. While pharmacokinetics of AIGIV were not altered by vaccination, the vaccine-induced immune response was abrogated in AIGIV-treated animals.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom